ACHN - Achillion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Achillion Pharmaceuticals, Inc.

VEVA Building #14
Suite 200 1777 Sentry Parkway West
Blue Bell, PA 19422
United States

Full Time Employees56

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph TruittPres, CEO & Director773.77kN/A1965
Mr. Paul FirutaExec. VP & COO462.03kN/A1966
Mr. Anthony S. GibneyExec. VP & Chief Bus. Officer408.66kN/A1971
Dr. Steven L. ZelenkofskeExec. VP & Chief Medical Officer314.81kN/A1959
Mr. Brian R. Di DonatoCFO, SVP & TreasurerN/AN/A1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Corporate Governance

Achillion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.